Application of polygala tenuifolia extract in treating attention deficit hyperactivity disorder
The present invention relates to the use of a composition comprising a polygala tenuifola Will plant extract (e.g., PDC-1421) for the preparation of a pharmaceutical product for the treatment of attention deficit hyperactivity disorder (ADHD). The composition comprises a polygala tenuifola Will plan...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
04.04.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to the use of a composition comprising a polygala tenuifola Will plant extract (e.g., PDC-1421) for the preparation of a pharmaceutical product for the treatment of attention deficit hyperactivity disorder (ADHD). The composition comprises a polygala tenuifola Will plant extract, e.g., PDC-1421. The composition of the present invention can be prepared into a gelatin capsule, and oral administration of the composition at a daily dose of between 380 mg and 3800 mg in a healthy subject is safe and well tolerant. The composition can be taken for at least 25 days for a long time; the daily dosage can be one time a day, two times a day or three times a day, and each dose contains 380-760 mg of the plant extract.
本发明关于一种包含远志(Polygala tenuifoliaWilld)植物萃取物(如PDC-1421)的组合物用于制备治疗注意力不足过动症(ADHD)的医药品的用途。本发明的组合物可制备成一种明胶胶囊,且于健康受试者中,以介于380mg至3800mg的每日剂量口服该组合物是安全且耐受良好的。本发明的组合物可长期服用至少25天;每日剂量可以一日一次、一日两次或一日三次的方式投药,其中每剂含有380-760mg的植物萃取物。 |
---|---|
Bibliography: | Application Number: CN20218001615 |